Stockscreener 앱 받기
5.39
2.28%
0.12
시간 외 거래:
5.38
-0.010
-0.19%
Polypid Ltd 주식(PYPD)의 최신 뉴스
PolyPid (PYPD): Will The November FDA Decision Propel The Stock? - RTTNews
PolyPid (PYPD) Stock: Finishes 0.59% Up at $5.13 in the Current Update; Trading Range - dars.gov.et
PolyPid (PYPD) Q2 2026 Results: Profit Per Share Surpasses Its Benchmark in the Current Update; Closing Reaction: Shares Close 1.40% Higher in Latest TradingRetail Earnings Report - vinanet.vn
PolyPid | 3: Initial statement of beneficial ownership of securities- Warshavsky Ori - Moomoo
PolyPid | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16] - Moomoo
AIGH Capital Management LLC Purchases Shares of 1,504,741 PolyPid Ltd. $PYPD - MarketBeat
PolyPid Ltd (PYPD) Stock News Today - TradingKey
PolyPid Ltd. (PYPD) Holds Near $4.75 as Clinical-Stage Biotech Navigates Key Support ZoneCall Resistance - vinanet.vn
Conferencia de resultados del 2T de 2026 de PolyPid (PYPD): revisión prioritaria de D-PLEX100 y acuerdo con Azurity - TradingKey
What is HC Wainwright's Forecast for PolyPid Q3 Earnings? - MarketBeat
PolyPid (PYPD) Earnings Call zum 2. Quartal 2026: Prioritäre Prüfung für D-PLEX100 und Azurity-Deal - TradingKey
PYPD|PolyPid Ltd|Price:4.690|Chg%:-0.080 - TradingKey
Roth MKM Maintains PolyPid(PYPD.US) With Buy Rating, Cuts Target Price to $8 - Moomoo
PolyPid (PYPD) investors disclose up to 13.4% beneficial stake via complex structure - Stock Titan
PolyPid Ltd. (PYPD) Slips 2.27% to $4.73 as Shares Test Key Support ZoneBollinger Walk - dars.gov.et
HC Wainwright Issues Negative Estimate for PolyPid Earnings - MarketBeat
PolyPid Earnings Call: Priority Review, Big Azurity Deal - TipRanks
PolyPid Ltd (PYPD) (Q2 2026) Earnings Call Highlights: FDA Priority Review and $30M Azurity ... - Yahoo Finance
PolyPid Posts Wider H1 2026 Loss as Assets and Equity Decline - TipRanks
PolyPid Ltd. Q2 2026 Earnings Call Summary - Yahoo Finance
PolyPid (PYPD) secures $30M Azurity payments but flags going concern risk - Stock Titan
Transcript : PolyPid Ltd., Q2 2026 Earnings Call, Aug 12, 2026 - marketscreener.com
Rosalind entities (PYPD) report 9.9% PolyPid stake, with 4.56M warrant shares blocked at 9.99% - Stock Titan
PolyPid Releases Q2 2026 Financial Results - AlphaStreet
PolyPid (NASDAQ:PYPD) Announces Quarterly Earnings Results, Beats Estimates By $0.03 EPS - MarketBeat
PolyPid Q2 Earnings Call Highlights - NewsBreak: Local News & Alerts
PolyPid Q2 losses narrow 55%, FDA accepts D-PLEX100 NDA - scanx.trade
Earnings call transcript: PolyPid narrows loss in Q2 2026 as stock falls premarket - Investing.com Australia
PolyPid Ltd reports results for the quarter ended June 30Earnings Summary - TradingView
PolyPid Ltd. Reports Earnings Results for the Half Year Ended June 30, 2026 - marketscreener.com
PolyPid Wins FDA Priority Review for D-PLEX₁₀₀ and Locks In $30 Million Azurity Milestones - TipRanks
PYPD: FDA accepted NDA for D-PLEX 100; $30M milestone secured, cash runway projected into 2028 - tradingview.com
PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - The Manila Times
PolyPid (PYPD) secures D-PLEX100 FDA priority review and $30M Azurity deal - Stock Titan
Press Release: PolyPid Provides Corporate Update and Reports Second Quarter 2026 Financial Results - Moomoo
PYPD Q1 2026 Earnings: Narrower Loss of -$0.35 Beats Consensus by 20.81%Buyback Announcement Report - vinanet.vn
PolyPid Ltd (PYPD) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
PolyPid (PYPD) Projected to Post Quarterly Earnings on Wednesday - MarketBeat
PYPD Q2'26 Earnings: revenue estimate is 0 USD - TradingView
Polypid Gains Nda Acceptance and Priority Review for D-Plex100 and Announces Partnership with Azurity Pharmaceuticals - marketscreener.com
PolyPid to Report Second Quarter 2026 Financial Results and Operational Highlights on August 12, 2026 - The Manila Times
PolyPid to Report Second Quarter 2026 Financial Results and Host Conference Call on August 12, 2026 - Quiver Quantitative
PolyPid Q1 2026 Earnings: EPS Beats Estimates as Company Advances PipelineEarnings Manipulation Risk - vinanet.vn
PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review By Investing.com - Investing.com South Africa
PolyPid stock jumps as FDA accepts D-PLEX100 NDA with priority review - Investing.com Nigeria
PolyPid Announces FDA Acceptance of NDA with Priority Review for D-PLEX₁₀₀ - GlobeNewswire
FDA grants priority review to PolyPid's D-PLEX1... - Pluang
PolyPid Ltd. Revenue Breakdown – NASDAQ:PYPD - TradingView
PolyPid Ltd (PYPD) Balance Sheet - tradingkey.com
PolyPid Ltd (PYPD) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
PYPD|PolyPid Ltd|Price:3.950|Chg%:+0.050 - TradingKey
PYPD|PolyPid Ltd|Price:4.290|Chg%:-0.080 - TradingKey
PolyPid Ltd (PYPD) Earnings Date & Reports & Earnings News - TradingKey
PolyPid Ltd (PYPD) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
PolyPid Ltd (PYPD) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
PolyPid Ltd (PYPD) Institutional Confidence - TradingKey
PolyPid Ltd (PYPD) Valuation: PE, PB & Fair Value Analysis - TradingKey
PolyPid Ltd (PYPD) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
PolyPid Ltd (PYPD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
PolyPid Ltd (PYPD) Income Statement - TradingKey
Short Interest in PolyPid Ltd. (NASDAQ:PYPD) Expands By 235.2% - MarketBeat
TradingKey - TradingKey
PolyPid, Azurity Sign US$330M Deal for D-PLEX100 - Streetwise Reports
Antibacterial Drug Partnership Accelerates PolyPid Commercial Path - Streetwise Reports
0.86%
0.31%
자본화:
|
볼륨(24시간):